Cells from patients' own blood spur cancer remissions

 

Pennsylvania

Nine leukemia patients are cancer-free after being treated with genetically-altered versions of their own immune cells, giving strength to a promising new approach for treating the blood cancer.

The trial of 12 patients, two of them children, bolsters findings from 2011. Then, scientists from the University of Pennsylvania in Philadelphia reported that two of the first three patients treated showed no traces of the malignancy after getting the therapy. Today's results were presented at the American Society of Hematology's annual meeting in Atlanta.

For Walter Keller, 59, who had failed every other treatment for his chronic lymphocytic leukemia diagnosed in 1996, the regimen meant he's been in remission since his treatment in April. Before the therapy, "I thought I had a year to live," he said.

"I feel better than I have in a long, long time," said Keller, of Upland, Calif., in a telephone interview. "I'm excited because I think this will help a lot of people."

The approach developed by University of Pennsylvania scientists has since been acquired by Novartis.

The scientists, led by Carl June, a professor of pathology and laboratory medicine at the Abramson Cancer Center at the University of Pennsylvania and a study author, used genetic engineering to manipulate white blood cells extracted from the patients. The researchers reprogrammed the cells to specifically target the leukemia cells and reinjected them into the patients.

CLL is a slow-growing cancer that starts from white blood cells in the bone marrow and interferes with the production of healthy blood cells. The condition leads to complications such as immune deficiencies and swollen lymph nodes. The disease strikes about 16,000 adults each year and 4,600 die from it, according to the American Cancer Society.

The disease is treated with chemotherapy. Another approach is bone marrow transplant in which chemotherapy is first given to kill diseased cells then replaced with healthy ones from bone marrow extracted from the patient or a donor.

Keller underwent chemotherapy and then a stem cell transplant in 1998 and 1999. He was in remission for 5 and a half years. He then underwent a different chemotherapy regimen and got a second stem cell transplant. The cancer came back again in 2010, and he had no options left. He was one of 10 adult patients treated so far.

"No patient who had complete remission has lost it," said Keller's doctor, David Porter, director of blood and marrow transplantation at the University of Pennsylvania's Abramson Cancer Center. "It's unusual to have a treatment that can work to this magnitude and until now, this duration."

Two of the original three patients treated have maintained their remissions over 2 years later. The scientists found signs of the designer blood cells still circulating in their bodies.

Two girls, ages 7 and 10, were also treated for a fast- growing blood cancer that affects children called acute lymphoblastic leukemia. Both had been treated and had then relapsed, said Stephan Grupp, director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. He presented research on their care at the hematology meeting.

One of the girls has been in complete remission in the 8 months since her treatment. The other had a remission of "a few months" before relapsing again, Grupp said. The younger girl had severe side-effects.

Previous studies have documented severe, flu-like illness in patients treated with their pumped-up immune cells. The 7- year-old's severe reaction helped explain what was happening, Grupp said. Her levels of an inflammatory protein called IL-6 were very high, 998 times her ordinary level. His group treated her with Roche's Actemra, approved for rheumatoid arthritis, which targets the protein. Because her levels of another inflammatory protein called TNF were high, she was also treated with Amgen and Pfizer's Enbrel.

"The next morning, she was dramatically better," Grupp said.

Her reaction suggests that the illness caused by the treatment is the result of an overactive immune system. Previously it wasn't clear what had caused the reactions, since tumors also release poisons when they're broken up to be cleared from the system.

Three adults being dosed with their own altered immune cells were also treated with Actemra, which lowered high fevers, restored abnormally low blood pressure, and allowed patients to easily breathe again.

"Everyone says I look good," said Keller, who also experienced flu symptoms after the treatment. "I guess I looked like crap before."

Novartis funded a $20 million research center at the University of Pennsylvania in Philadelphia, as well as paying an undisclosed amount of money for rights to the therapy in August. The therapy will be called CTL019 by the drugmaker.

Today's research was funded by the Leukemia & Lymphoma Society, the Alliance for Cancer Gene Therapy and the National Institutes of Health.

Start your day with The Independent, sign up for daily news emails
Have you tried new the Independent Digital Edition apps?
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Ashdown Group: Training Coordinator - Financial Services

£32000 - £38000 per annum + benefits: Ashdown Group: A highly successful, inte...

Recruitment Genius: Supply Chain Administrator

£8000 - £10800 per annum: Recruitment Genius: A Supply Chain Administrator is ...

Recruitment Genius: Client IT Account Manager

£25000 - £30000 per annum: Recruitment Genius: A Client IT Account Manager is ...

Day In a Page

No postcode? No vote

Floating voters

How living on a houseboat meant I didn't officially 'exist'
Louis Theroux's affable Englishman routine begins to wear thin

By Reason of Insanity

Louis Theroux's affable Englishman routine begins to wear thin
Power dressing is back – but no shoulderpads!

Power dressing is back

But banish all thoughts of Eighties shoulderpads
Spanish stone-age cave paintings 'under threat' after being re-opened to the public

Spanish stone-age cave paintings in Altamira 'under threat'

Caves were re-opened to the public
'I was the bookies’ favourite to be first to leave the Cabinet'

Vince Cable interview

'I was the bookies’ favourite to be first to leave the Cabinet'
Election 2015: How many of the Government's coalition agreement promises have been kept?

Promises, promises

But how many coalition agreement pledges have been kept?
The Gaza fisherman who built his own reef - and was shot dead there by an Israeli gunboat

The death of a Gaza fisherman

He built his own reef, and was fatally shot there by an Israeli gunboat
Saudi Arabia's airstrikes in Yemen are fuelling the Gulf's fire

Saudi airstrikes are fuelling the Gulf's fire

Arab intervention in Yemen risks entrenching Sunni-Shia divide and handing a victory to Isis, says Patrick Cockburn
Zayn Malik's departure from One Direction shows the perils of fame in the age of social media

The only direction Zayn could go

We wince at the anguish of One Direction's fans, but Malik's departure shows the perils of fame in the age of social media
Young Magician of the Year 2015: Meet the schoolgirl from Newcastle who has her heart set on being the competition's first female winner

Spells like teen spirit

A 16-year-old from Newcastle has set her heart on being the first female to win Young Magician of the Year. Jonathan Owen meets her
Jonathan Anderson: If fashion is a cycle, this young man knows just how to ride it

If fashion is a cycle, this young man knows just how to ride it

British designer Jonathan Anderson is putting his stamp on venerable house Loewe
Number plates scheme could provide a licence to offend in the land of the free

Licence to offend in the land of the free

Cash-strapped states have hit on a way of making money out of drivers that may be in collision with the First Amendment, says Rupert Cornwell
From farm to fork: Meet the Cornish fishermen, vegetable-growers and butchers causing a stir in London's top restaurants

From farm to fork in Cornwall

One man is bringing together Cornwall's most accomplished growers, fishermen and butchers with London's best chefs to put the finest, freshest produce on the plates of some of the country’s best restaurants
Robert Parker interview: The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes

Robert Parker interview

The world's top wine critic on tasting 10,000 bottles a year, absurd drinking notes and New World wannabes
Don't believe the stereotype - or should you?

Don't believe the stereotype - or should you?

We exaggerate regional traits and turn them into jokes - and those on the receiving end are in on it too, says DJ Taylor